Cadila Healthcare has received warning notice from US Food and Drug Administration (US FDA) for violating manufacturing standards at two plants in Moraiya and Ahmedabad in Gujarat.More than 40 percent of the generic and over the counter medicines available in the United States comes from Indian facilities such as Cadila's Moraiya plant.Cadila Healthcare, the flagship company of Zydus group, posted a standalone net profit of Rs 614 crore for the quarter ended September 30, 2015 as compared to Rs 365 crore in the year-ago period. The standalone total income of the company increased to Rs 1,976 crore during the quarter from Rs 1,396 crore for the year-ago quarter.During the quarter, on a consolidated basis, its US sales rose 25 per cent to Rs 1,004 crore.
